Eli Lilly and Co (NYSE:LLY) released topline results from two Phase 3 studies on Thursday.
Get notified with breaking news, our articles and more!
Follow us
The pharmaceutical company evaluated insulin efsitora alfa (efsitora), administered once a week, in patients with type 2 diabetes who are using insulin for the first time (insulin naïve) and in those requiring multiple injections of insulin per day.
In treat-to-target clinical trials, efsitora demonstrated non-inferior A1C reductions compared to the most commonly used daily basal insulins globally.
QWINT-2 evaluated the efficacy and safety of efsitora once weekly compared to insulin degludec once daily for 52 weeks.
The study met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 52.
Regarding the efficacy estimate, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec, with a reduction in A1C of 6.87% and 6.95%, respectively .
In a key secondary endpoint, efsitora was non-inferior to insulin degludec for change in A1C between participants using and not using GLP-1 receptor agonists.
Additionally, participants taking efsitora spent 45 minutes longer in the range and 37 minutes longer in the narrow range without becoming hypoglycemic (blood glucose <54 mg/dL) compared to insulin degludec.
QWINT-4 evaluated the efficacy and safety of efsitora versus insulin glargine over 26 weeks in adults with type 2 diabetes previously treated with basal insulin and at least two daily mealtime insulin injections.
Regarding the efficacy estimate, efsitora and insulin glargine reduced A1C by 1.07%, resulting in A1C of 7.12% and 7.11%, respectively.
In QWINT-2 and QWINT-4, efsitora was safe and well tolerated.
Estimated rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 0.58 with efsitora vs. 0.45 with insulin degludec (QWINT-2) and 6.6 with efsitora vs. 5.9 with insulin glargine (QWINT-4).
Results from QWINT-1, QWINT-3 and QWINT-5 are expected later this year.
LLY stock price
LLY shares were down 0.43% at $783.65 at last check on Thursday.
For more updates on this topic, add Benzinga Italy to your favorites or follow us on our social channels: X And Facebook.
Receive exclusive insights into market movements 30 minutes before other traders
The 14-day free trial of Benzinga Pro, available in English only, gives you access to exclusive information so you can receive actionable trading signals before millions of other traders. CLICK HERE to start your free trial.
Image: Shutterstock
